A public, self-enrollment registry to track a large population of COVID-19 immunity responses in vaccinated participants, participants with a previous infection, and participants with previous infection who have been vaccinated
Since March 2020, the world has been navigating its way through the COVID-19 pandemic. Millions have died from COVID-19, while at the same time, many more millions have been infected with the virus and recovered. A variety of vaccines are now available to combat the virus. Both vaccines and COVID-19 recoveries create antibodies that fight off reinfection of the virus. But many questions remain that the COVID-19 Antibody Registry (CAR) hopes to provide answers for:
- How long does immunity last when vaccinated by any of the vaccines, particularly those most commonly used?
- Are certain demographic groups at greater risk?
- Is a super immunity created for participants who have both recovered from the virus and received a vaccination?
- How long does immunity last for participants who have recovered from COVID-19?
- When does COVID-19 immunity begin to weaken?
- Are IgG antibodies present in a breakthrough case (COVID-19 infection in a person who is fully vaccinated)?
By learning how antibody levels increase or decrease over time, our goal is to better understand just how immunity works.
The CAR study evaluates antibody concentrations in participants who have either tested positive for COVID-19, received one of the available vaccines, or both. CAR is available to any person in the world with some sort of COVID-19 immunity who is willing to take an antibody test. Voluntary participation in this registry will require your consent to share your data without divulging your identity.
CAR data is securely stored in TrialKit’s cloud database. TrialKit is a data collection and study management solution that is compliant with 21 CFR Part 11 guidelines, GDPR, HIPAA, EMEA Annex 11, ICH Q9, ISO 9001:2015, ISO/IEC 27001:2013, SOC Type 2, Privacy Shield EU-US, and HiTrust. As enough data is aggregated, study results by time period will be published. The registry could lead to more detailed studies that collect more specific data, as well as individual tests to determine more long-term immunity.
Participating in the CAR study is simple and straightforward:
Access the CAR Instruction Guide to help you enroll today.
Questions about joining the CAR study? Get in touch with us: CARregistry@trialkit.com
Learn more about Crucial Data Solutions and TrialKit
Crucial Data Solutions, Inc. is dedicated to developing innovative technologies that reduce the cost of research when in the hands of those performing the research. We equip research professionals with advanced tools that make it easier and more affordable to advance treatments and improve the quality of life for all those involved. We approach clinical research as a partnership with research professionals, caregivers, and patients worldwide.
TrialKit, our cloud-based platform available via a web interface and downloadable native mobile app, enables end-to-end clinical trial management for pharmaceutical, biotechnology, and medical device companies of all sizes. Over 10,000 global users have leveraged the flexibility of TrialKit to deploy over 7,000 studies across all phases of drug and device development.
Visit www.crucialdatasolutions.com
